Equine allogeneic chondrogenic induced mesenchymal stem cells are an effective treatment for degenerative joint disease in horses.

Degenerative joint disease is one of the main causes of equine early retirement from pleasure riding or a performance career. The disease is initially triggered by an abnormal loading of normal cartilage or a normal loading of abnormal cartilage. This primary insult is accompanied with joint inflammation, which leads to further progressive degeneration of the articular cartilage and changes in the surrounding tissues. Therefore, in search for an effective treatment, 75 adult horses with early signs of degenerative fetlock joint disease were enrolled in a randomized, multicenter, double blinded, and placebo controlled study. Fifty animals were injected intra-articularly with the investigational veterinary product consisting of allogeneic chondrogenic induced mesenchymal stem cells (ciMSCs) with equine allogeneic plasma, and 25 horses were injected with 0.9% NaCl (saline) control product (CP). From week 3 to 18 after treatment, lameness scores (P<0.001), flexion test responses (P<0.034) and joint effusion scores (P<0.001) were remarkably superior in investigational veterinary product treated horses. Besides nasal discharge in both treatment groups, no adverse events were observed during the entire study period. On long term follow-up (one year), significantly more investigational product treated horses were working at training level or were returned to their previous level of work (P <0.001).